Akari Therapeutics ADR (AKTX) Stock Price, Quote & News

Company Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads in...

Industry: Biotechnology

Sector: Healthcare

Phone: 929 274 7510

Fax: 929 274 7553

Website: www.akaritx.com

Address:

22 Boston Wharf Road, Floor 7, Boston, United States

TwongStocks Mar. 27 at 8:18 PM

$AKTX Equity Corporate Actions Alert #2026 - 196 Information Regarding the Reverse Stock Split, Ratio Change and CUSIP Number Change for Akari Therapeutics, Plc (AKTX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-196 Akari Therapeutics, Plc (AKTX) will effect a one-for-forty (1-40) reverse split of its American Depositary Shares and ratio change from one (1) Depositary Share representing two thousand (2,000) Ordinary Shares (1:2,000) to one (1) Depositary Share representing eighty thousand (80,000) Ordinary Shares (1:80,000). The reverse stock split and ratio change will become effective on Tuesday, March 31, 2026. In conjunction with the reverse split, the CUSIP number will change to 00972G405.

0 · Reply

coachmc Mar. 26 at 3:00 PM

$AKTX you know it’s over when Nick taps out and also went bearish. 😆

0 · Reply

Noname66 Mar. 24 at 3:11 PM

$AKTX ATM

0 · Reply

toxicdogie Mar. 20 at 11:47 AM

$AKTX $AZTR Woweeee

0 · Reply

toxicdogie Mar. 20 at 8:43 AM

$AZTR +$AKTX 👀👀🚀

1 · Reply

costrexx Mar. 19 at 8:13 PM

$AKTX

0 · Reply

Noname66 Mar. 19 at 5:29 PM

$AKTX Any one remember the last time AKTX done a reverse split????

1 · Reply

Noname66 Mar. 19 at 4:49 PM

$AKTX Any one know when is the last time AKTX do a ATM move?

0 · Reply

jennybaby Mar. 19 at 3:15 PM

$AKTX all of us who said that we would “go down to zero” are about to get our wish come true. I am now convinced that this was always a scam! all of these “reputable” doctors taking over are a joke. Don’t fall for how “oversold” this is. Once the share price becomes complaint, they will short it to the ground again. Stay away!! It’s the best advice you will ever get.

2 · Reply

BigBull005 Mar. 18 at 10:48 PM

$AKTX we are so close to zero - oh lord take me away

0 · Reply

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

Mar 17, 2026, 4:30 PM EDT - 10 days ago

Akari Therapeutics Announces ADS Ratio Change

Mar 13, 2026, 9:15 AM EDT - 14 days ago

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

Feb 26, 2026, 9:10 AM EST - 4 weeks ago

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

Feb 18, 2026, 9:05 AM EST - 5 weeks ago

Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

Feb 11, 2026, 8:45 AM EST - 6 weeks ago

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline

Feb 5, 2026, 9:15 AM EST - 7 weeks ago

Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Jan 26, 2026, 8:45 AM EST - 2 months ago

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Jan 9, 2026, 9:00 AM EST - 2 months ago

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Jan 8, 2026, 9:15 AM EST - 2 months ago

Akari Therapeutics to Present at the 2026 Biotech Showcase

Dec 30, 2025, 9:15 AM EST - 3 months ago

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

Dec 23, 2025, 8:30 AM EST - 3 months ago

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

Dec 18, 2025, 8:30 AM EST - 3 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Dec 16, 2025, 9:29 AM EST - 3 months ago

Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market

Dec 9, 2025, 8:40 AM EST - 3 months ago

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

Dec 4, 2025, 9:00 AM EST - 4 months ago

Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment

Nov 25, 2025, 9:00 AM EST - 4 months ago

Akari Therapeutics Announces Release of the Next CEO Corner Segment

Nov 18, 2025, 8:35 AM EST - 4 months ago

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

Nov 10, 2025, 8:30 AM EST - 4 months ago

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

Nov 4, 2025, 9:25 AM EST - 5 months ago

Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

Oct 30, 2025, 8:35 AM EDT - 5 months ago

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

Oct 22, 2025, 9:05 AM EDT - 5 months ago

Akari Therapeutics Announces Launch of CEO Corner Platform

Oct 15, 2025, 8:30 AM EDT - 5 months ago

Akari Therapeutics Announces $2.5 Million Registered Direct Offering

Oct 9, 2025, 8:45 AM EDT - 6 months ago

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

Oct 3, 2025, 9:30 AM EDT - 6 months ago

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Sep 24, 2025, 8:45 AM EDT - 6 months ago

Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Sep 17, 2025, 8:45 AM EDT - 6 months ago

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

Sep 5, 2025, 6:45 AM EDT - 7 months ago

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 7 months ago

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Aug 14, 2025, 9:15 AM EDT - 8 months ago

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 23, 2025, 8:55 AM EDT - 8 months ago

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Jul 22, 2025, 8:45 AM EDT - 8 months ago

Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jun 25, 2025, 9:00 AM EDT - 9 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Jun 18, 2025, 8:50 AM EDT - 10 months ago

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

May 29, 2025, 9:15 AM EDT - 10 months ago

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

May 22, 2025, 9:00 AM EDT - 11 months ago

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 19, 2025, 8:00 AM EDT - 11 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

CRBP QURE

May 15, 2025, 8:05 AM EDT - 11 months ago

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 1, 2025, 8:45 AM EDT - 11 months ago

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

Apr 22, 2025, 9:05 AM EDT - 1 year ago

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Mar 20, 2025, 8:35 AM EDT - 1 year ago

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Mar 3, 2025, 9:00 AM EST - 1 year ago

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Feb 19, 2025, 9:00 AM EST - 1 year ago

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 3, 2025, 8:00 AM EST - 1 year ago

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Dec 18, 2024, 8:51 AM EST - 1 year ago

Akari Therapeutics Announces Key Leadership Appointments

Dec 16, 2024, 9:05 AM EST - 1 year ago

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Nov 14, 2024, 4:15 PM EST - 1 year ago

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Nov 8, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Aug 19, 2024, 4:15 PM EDT - 1 year ago

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

TwongStocks Mar. 27 at 8:18 PM

0 · Reply

coachmc Mar. 26 at 3:00 PM

$AKTX you know it’s over when Nick taps out and also went bearish. 😆

0 · Reply

Noname66 Mar. 24 at 3:11 PM

$AKTX ATM

0 · Reply

toxicdogie Mar. 20 at 11:47 AM

$AKTX $AZTR Woweeee

0 · Reply

toxicdogie Mar. 20 at 8:43 AM

$AZTR +$AKTX 👀👀🚀

1 · Reply

costrexx Mar. 19 at 8:13 PM

$AKTX

0 · Reply

Noname66 Mar. 19 at 5:29 PM

$AKTX Any one remember the last time AKTX done a reverse split????

1 · Reply

Noname66 Mar. 19 at 4:49 PM

$AKTX Any one know when is the last time AKTX do a ATM move?

0 · Reply

jennybaby Mar. 19 at 3:15 PM

2 · Reply

BigBull005 Mar. 18 at 10:48 PM

$AKTX we are so close to zero - oh lord take me away

0 · Reply

newyork1979 Mar. 18 at 6:54 PM

TAOP could easily 3X from here - 900k FLoat with no dilution - Robotics / AI merger coming with a company that has HUGE customers like mcdonals/KFC/Starbucks - TAOP is only valued around $12M , very undervalued. - Shorts are trapped and will be forced to buyback all their shares which will cause a Mother of all short squeezes. $OCG $GANX $GSIT $AKTX $TGEN Watching

0 · Reply

toxicdogie Mar. 18 at 2:58 PM

$AKTX Thus is way and stupidly oversold This price and market cap- loading ta fuk up big time here Extremely discounted

0 · Reply

Bart69 Mar. 18 at 2:57 PM

$AKTX "The Ratio Change will result in a one for forty reverse split" https://www.sec.gov/Archives/edgar/data/1541157/000149315226010602/form8-k.htm Well, I sold some after news but still stuck here. Interesting insider trade prior day. https://www.sec.gov/Archives/edgar/data/1600865/000149315226010304/xslF345X05/ownership.xml

0 · Reply

Moneyboy231 Mar. 18 at 2:28 PM

$AKTX good or bad?

0 · Reply

stockscan Mar. 18 at 2:04 PM

$AKTX https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-announces-abstract-accepted-poster

0 · Reply

Nick1971 Mar. 17 at 10:46 PM

$AKTX what a joke

0 · Reply

Htsone Mar. 17 at 9:21 PM

$AKTX This company is such a loser. Like my investment here. Fortunately I sold almost all back in September for an 80% loss, and thankfully i hadn't pumped much in. Hopefully ol' Chauderhead is still feeling like it's something.

0 · Reply

Vale0000 Mar. 17 at 8:54 PM

$AKTX still holding

0 · Reply

Bart69 Mar. 17 at 8:38 PM

$AKTX Oh boy.

0 · Reply

DonCorleone77 Mar. 17 at 8:37 PM

$AKTX Akari Therapeutics announces ADS ratio change Akari Therapeutics announced that the company will change the ratio of its American depositary shares to ordinary shares from one ADS representing 2,000 ordinary shares to a new ratio of one ADS representing eighty thousand 80,000 ordinary shares. The ratio change is expected to be effective on March 31. The ratio change is intended to enable Akari to maintain compliance with the Nasdaq minimum bid price requirement for continued listing. On the effective date, each ADS holder will be required to exchange every forty ADSs for one new ADS. Deutsche Bank, the depositary bank, will arrange for the exchange of the current ADSs for the new ADSs. There is no change to Akari's underlying ordinary shares, and Akari's ADSs will continue to trade on the Nasdaq Capital Market under the symbol (AKTX).

0 · Reply

toxicdogie Mar. 17 at 8:29 AM

$AKTX .28 overnight trading Hmmmmm

0 · Reply

Roger74c Mar. 16 at 3:44 PM

$AKTX Goodbye

0 · Reply

Market Cap	6.25M
Revenue (ttm)	0.00
Net Income (ttm)	-19.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.03

Volume	385,800
Avg Vol	352,014
Day's Range	N/A - N/A
Shares Out	45.78M
Stochastic %K	6%
Beta	0.29
Analysts	Strong Sell
Price Target	$2.65